Implementing a Basal-Bolus Insulin Regimen Via a Manual Insulin Pump Device by Stearns, Helen
University of San Diego 
Digital USD 
Doctor of Nursing Practice Final Manuscripts Theses and Dissertations 
Spring 5-23-2020 
Implementing a Basal-Bolus Insulin Regimen Via a Manual Insulin 
Pump Device 
Helen Stearns 
University of San Diego, hstearns@sandiego.edu 
Follow this and additional works at: https://digital.sandiego.edu/dnp 
 Part of the Endocrine System Diseases Commons, and the Nursing Commons 
Digital USD Citation 
Stearns, Helen, "Implementing a Basal-Bolus Insulin Regimen Via a Manual Insulin Pump Device" (2020). 
Doctor of Nursing Practice Final Manuscripts. 112. 
https://digital.sandiego.edu/dnp/112 
This Doctor of Nursing Practice Final Manuscript is brought to you for free and open access by the Theses and 
Dissertations at Digital USD. It has been accepted for inclusion in Doctor of Nursing Practice Final Manuscripts by 
an authorized administrator of Digital USD. For more information, please contact digital@sandiego.edu. 
IMPLEMENTING A BASAL-BOLUS REGIMEN  1










Implementing a Basal-Bolus Insulin Regimen Via a Manual Insulin Pump Device 
Helen R. Stearns 










IMPLEMENTING A BASAL-BOLUS REGIMEN  2
Abstract 
Purpose: The purpose of this evidence-based practice project is to decrease glycated 
hemoglobin (HgbA1C) levels by initiating use of a manual insulin pump in patients with Type II 
Diabetes Mellitus (T2DM) with poor glycemic control who are on multiple daily insulin 
injections (MDII). 
Background: Uncontrolled hyperglycemia is associated with a myriad of complications 
and co-morbidities that are generally associated with vascular changes that include nephropathy, 
neuropathy, blindness, stroke, and heart disease (Winter et al., 2015). Coronary artery disease 
and cerebrovascular disease alone accounts for approximately 65% of the deaths in diabetic 
patients (Molinaro & Dauscher, 2017). Achieving and maintaining therapeutic glycemic levels, 
blood pressure, and lipid control is essential in the prevention of these complications (Molinaro 
& Dauscher, 2017). A randomized clinical trial showed that initiation of a manual insulin pump 
in patients with T2DM with poor glycemic control reduced HgbA1C levels by ≥1% in 73% of 
patients (Lajara, Nikkel, et al., 2016). A meta-analysis study showed that at 6 months, HgbA1C 
levels decreased 1.1% with use of an insulin pump compared to a 0.4% reduction with MDII 
(Reznik et al., 2014).  
Medical expenditures are approximately 2.3 times higher for people with diabetes than 
those without diabetes (American Association of Diabetes, 2018). Diabetic medications account 
for 43% of the medical burden with almost $15 billion spent on insulin alone, putting the total 
estimated cost of diabetes in the U.S. at $327 billion (ADA, 2018).  
Outcomes: The goal for this project is ≥1% reduction in HgbA1c. 
Process: Patients with T2DM in a southern California underserved community health 
center were assessed and identified for eligibility for placement of a manual insulin pump device. 
Data collection included HgbA1C levels prior to initiation of the pump and post-initiation per 
clinic protocols and provider orders.  Patients were followed up for ongoing education and 
assessment as needed by the clinical pharmacist and clinic providers.  
Results: Use of the insulin pump showed a mean significant decrease of -1.26% in 
HgbA1C levels.  
Implications for Clinical Practice: The implementation of a simple insulin delivery 
system that improves glycemic controls in patients with T2DM is an evidence-based strategy 
providers can use to help patients manage uncontrolled diabetes, improve national diabetes score 
outcomes, lessen complications, increase treatment persistency and decrease harmful sequelae 
resulting from poorly controlled glycemic indexes. 
Conclusions: Delivery via a basal-bolus regimen is still the gold standard for insulin 
therapy, and innovations in insulin delivery systems have helped patients achieve therapeutic 
glycemic levels. Initiating simple insulin delivery systems into eligible diabetic patient 
populations who have failed other pharmacological therapy may decrease financial expenditures, 
complications, and comorbidities associated with this disease. 
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Background and Evidence for the Problem 
Since 1980, the number of people in the United States (US) with diabetes has increased 
fourfold (Carls et al., 2017). The Center for Disease Control (CDC) estimates that in 2018, the 
U.S. had 1.5 million new cases of diabetes in the adult population (Center for Disease Control, 
2020). In 2017, an estimated 24.7 million people in the US had a diagnosis of diabetes estimating 
the cost of diabetes at $327 billion, a figure that includes direct health care expenditures, lost 
productivity, disability related unemployment, and premature mortality (ADA, 2018).  
 Annually, the average medical expenses for a person with diabetes is about $16,750 - 
approximately 2.3 times higher for people with diabetes than for those without diabetes. Diabetic 
medications alone are accountable for 43% of the medical burden and include an almost $15 
billion price tag for insulin alone. In 2017, approximately 25% of the projected 162 million 
hospital inpatient days, 25% nursing home and residential facility days, and 50% of outpatient 
office visits, emergency department (ED) visits, and physician office visits were incurred by 
patients with diabetes (ADA, 2018). 
Uncontrolled hyperglycemia is associated with a myriad of complications and co-
morbidities that are generally associated with vascular changes that include nephropathy, 
neuropathy, blindness, stroke, and heart disease (Winter et al., 2015). Coronary artery disease 
and cerebrovascular disease alone accounts for approximately 65% of the deaths in patients with 
diabetes (Molinaro & Dauscher, 2017). Achieving and maintaining therapeutic glycemic levels, 
blood pressure, and lipid control is essential in the prevention of these complications (Molinaro 
& Dauscher, 2017). 
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Evidence-Based Intervention and Benchmark 
Optimal Insulin Therapy Regimen 
Diabetic treatment is generally guided by HgbA1C levels and is used by multiple 
organizations as a measure of quality of care for Type 2 Diabetes Mellitus (T2DM) including the 
National Quality Forum, and is also utilized in Medicare star ratings, and the Healthcare 
Effectiveness Data and Information Set.  Both the American Diabetes Association (ADA) and 
the European Association for the Study of Diabetes (EASD) utilize the HgbA1C levels as a 
target for clinical guidelines (Carls et al., 2017). 
The ADA, EASD, and the American Association of Clinical Endocrinologists all 
acknowledge the efficacy of utilizing a multi-drug, individualized approach to achieve HgbA1C 
goals in the absence of therapeutic glycemic control. Most often when a patient has failed to 
reach A1C goals on oral therapies, the first step recommended in insulin therapy is initiation of 
basal insulin.  This is often effective for controlling fasting plasma glucose (FPG) but does not 
usually achieve adequate postprandial plasma glucose (PPG) levels (Hinnen, 2015). There are 
inherent risks associated with adding mealtime insulin to a patient’s regimen including 
hypoglycemia, weight gain, and the burden of frequent glucose self-monitoring.  Despite these 
risks, basal-bolus insulin therapy remains the gold standard for insulin therapy, and allows doses 
to be altered and individualized to achieve therapeutic glycemic control (Hinnen, 2015).  
Compliance with MDI  
Initiating insulin therapy in patients with T2DM often presents with significant barriers to 
achieving treatment adherence and persistence.  Depending on the patient population studied and 
the standard of measurement used, rates of compliance for insulin use vary from 30% to 86% 
(Guerci et al., 2019). As a patient’s medication regimen becomes more complex, including, 
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notably, an increase in frequency of insulin injections, so too does the risk of nonadherence and 
poor treatment persistence (Guerci et al., 2019). Common adherence barriers identified by 
patients with T2DM include injection site reactions, time consuming and complicated insulin 
therapy regimen, number of required insulin injections, requirement for dosing at specific times, 
travelling, fear of hypoglycemia, and interference with lifestyle, weight gain, forgetfulness, 
embarrassment of injections in public, and sick days (Sarbacker & Urteaga, 2016).  Missing only 
four prandial insulin injections per week over three months has been correlated with an almost 
1% increase in HgbA1C levels (Lajara, Nikkel, et al., 2016).  Up to 57% of patients on MDI 
report missing injections with up to 20% of these patients report missing injections regularly 
(Lajara, Davidson et al., 2016).  
Nonadherence to insulin therapy is associated with an increase in hospitalizations, ED 
visits, worse health outcomes, and an increased all-cause mortality (DiBonaventura et al., 2014). 
A significant economic burden of nonadherence to insulin therapy is also primarily associated 
with increased hospital and ED admissions.  A study involving a large cohort of patients showed 
that an increase in medication compliance decreased hospitalizations or ED visits by 13% 
resulting in an annual cost-savings of $4.68 billion (Kennedy-Martin et al., 2017).  
Benefits of Continuous Subcutaneous Insulin Infusion vs Multiple Daily Insulin Injections 
Finding ways of mitigating nonadherence and addressing barriers is essential to achieving 
optimal medication compliance and therapeutic glycemic control.  Continuous subcutaneous 
insulin infusion (CSII) can be more effective than multiple daily insulin injections (MDII) in the 
treatment of Type 1 Diabetics (T1DM) and T2DM with poor glycemic control (Pickup et al., 
2017).  
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Initiation of a manual insulin pump in patients with T2DM with poor glycemic control 
has been shown to reduce HgbA1C levels by ≥1% in 73% of patients (Lajara, Nikkel, et al., 
2016).  Of a cohort of patients who previously did not achieve glycemic targets despite intense 
medication therapies, 71% of those placed on the CSII achieved glycemic targets (Lajara, 
Nikkel, et al., 2016).  A meta-analysis study of 590 poorly controlled T2DM patients showed 
HgbA1C levels decreased 1.1% with use of an insulin pump compared to a 0.4% reduction with 
MDII (Reznik et al., 2014).  Further, patients utilizing a manual insulin pump to deliver CSII 
therapy also achieved better glycemic control while using less insulin (Lajara, Davidson, et al., 
2016; Pickup et al., 2017).  
Requiring one daily insulin injection versus four results in significantly higher treatment 
adherence rates of 78.3% vs 60.8% (Guerci et al., 2019).  Manual insulin pumps may be a 
solution that obviates the need for MDI, addressing many of the barriers to adherence as 
identified by the T2DM patient population.  
Benchmark 
Every 1% in HbgA1C reduction is associated with a 37% reduction in microvascular 
complications, a 14% reduction in myocardial infarctions, and a 21% reduction in diabetes-
associated death rates (Lajara, Nikkel, et al., 2016).  Initiating use of CSII via use of a manual 
insulin pump has shown significant reduction of ≥1% HgbA1C levels in patients who previously 
had achieved no therapeutic change despite aggressive pharmacological interventions (Lajara, 
Nikkel, et al., 2016).  The benchmark for this project is a ≥1% reduction in HgbA1C levels.  
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Evidence-Based Practice Question (PICO) 
Does implementing the use of a manual basal-bolus insulin pump for patients with insulin 
dependent T2DM compared to multiple daily insulin injections (MDII) result in lower HgbA1C 
levels?  
Project Plan Process 
The site for this project was a southern California underserved community health center.  
Stakeholder buy-in, administration permission, and IRB approval were obtained prior to 
initiation of the implementation of the project and data collection.  Patients with T2DM with 
uncontrolled HgbA1C levels who had failed previous pharmacological therapy were identified 
for placement of a manual insulin pump device.  Data collection included HgbA1C levels prior 
to initiation of the pump and post-initiation per clinic protocols and provider orders.  Patients 
were followed up for ongoing education and assessment as needed by the clinical pharmacist and 
clinic providers.  
Evaluation Results 
Data were collected and analyzed on a sample population of 17 adult male and female 
patients.  There was a significant decrease in HgbA1C levels in all but two patients who were 
placed on the manual insulin pump.  Data are presented in Figure 1. The mean difference in 
HgbA1C levels was -1.26% which meets the anticipated benchmark of a reduction of ≥1% for 
this project. 
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Figure 1  
Pre/Post Hemoglobin A1C Levels 
 
  
Overall, patients’ comments about what they liked about the pump included not needing 
multiple daily injections, not feeling the pump needle, and an increased level of flexibility and 
freedom.  Patients’ caregivers reported the pump’s ease of use for their elderly patients.  Patients 
reported disliking the pump for a variety of reasons including feeling it on the abdomen when 
they sleep, feeling the needle when they move, trouble with needle retraction when removing the 
device, difficulty removing the pump, and confusion with the prescribed therapy.  
Barriers 
Barriers identified during this project included language and socio-economic factors 
contributing to comprehension difficulties regarding the pump device and prescribed therapy and 
non-adherence of follow-up visits. Very few insurance barriers were identified as both Medi-Cal 














A1c Before A1c After
Note. N= 17. Significant reduction in HgbA1c after placement of insulin pump (Mean Difference 
-1.26, t = 3.12, p < .01). 
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Cost-Benefit Analysis 
Evidence from real-world studies shows that patients who switch from MDI therapy to a 
manual insulin pump often require less insulin resulting in pharmacy savings up to $119.30 per 
month (Lajara, Nikkel, et al., 2016). Persistence use of a manual insulin pump vs MDI 
demonstrated cost-effectiveness by an incremental pharmacy cost-savings of $695.61 per every 
1% decrease in HgbA1C (Everitt et al., 2018). Research also suggests that decreased compliance, 
as has been documented with MDI therapy vs CSII therapy, results in worse health outcomes and 
increased overall healthcare costs (ADA, 2018; DiBonaventura et al., 2014; Guerci et al., 2019). 
Implications for Clinical Practice (Sustainability) 
Initiating use of a manual insulin pump into an outpatient primary care or endocrine 
clinic setting has a high level of sustainability. Trained healthcare providers supported by 
company representatives facilitate patient education and adherence with follow-up visits. The 
pump is a simple manual device and has no tubing, complicated settings, or batteries resulting in 
few, if any, documented device malfunctions or complications.  The pump requires only one type 
of insulin and patients do not require increased follow-up visits after initial education and device 
check visits. The pump is usually covered by insurance companies including Medicare along 
with reimbursement and insurance guidance offered by the manufacturer and company 
representatives (Zealand Pharma, 2020).  
Facilitating factors contributing to successessful implementation of manual insulin pumps 
was the clinic buy-in. The clinical pharmacist met individually with all patients for education and 
follow-up visits. Additionally, the clinic opened a diabetes clinic where patients were able to 
obtain follow up visits and care rather than waiting to see their primary care provider for any 
diabetes-related concerns or questions. The implementation of a simple insulin delivery system 
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that improves glycemic controls in T2DM is an evidence-based and sustainable strategy primary 
care providers can use to help patients manage uncontrolled diabetes, improve national diabetes 
score outcomes, lessen complications, and decrease harmful sequelae resulting from poorly 
controlled glycemic indexes. 
Conclusion 
Diabetes is a world-wide epidemic disease that is only increasing in numbers creating an 
enormous economic and healthcare burden globally (da Rocha Fernandes et al., 2016). 
Therapeutic glycemic control is of paramount importance in decreasing adverse effects 
associated with diabetes.  Improvements and innovations in insulin delivery systems have helped 
patients achieve therapeutic glycemic levels and improved quality of life.  Initiating insulin 
delivery systems based on the latest literature evidence into eligible diabetic patient populations 
may have lasting impact on quality of life, financial expenditures, and comorbidities associated 
with this disease. 
There are multiple factors to consider in the treatment of diabetes, including patients’ 
preferences and lifestyle, body mass index (BMI), severity of disease, and glycemic control 
(Hinnen, 2015).  Initiation of a manual insulin pump that delivers a basal-bolus insulin regimen 
into the populations with T2DM who have failed MDI and aggressive pharmacological therapy 
has been shown to be an effective way of lowering HgbA1C levels while addressing many 
patient concerns that contribute to failed MDI therapy.  
Results of this evidence-based practice project showed 88% of patients achieving a mean 
decreased HgbA1C levels of -1.26%.  Limitations of this study include a small sample size and a 
short duration of time.  Further studies would be helpful in measuring compliance, sustainability, 
and HgbA1C scores over a greater length of time with a larger sample size.  
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